Last reviewed · How we verify

Reyvow (LASMIDITAN)

Eli Lilly · FDA-approved approved Small molecule Quality 65/100

Reyvow works by binding to the 5-HT1F receptor, blocking pain signals in the brain.

Reyvow (Lasmiditan) is a small molecule developed by Eli Lilly and Co, targeting the 5-hydroxytryptamine receptor 1F. It is FDA-approved for the treatment of migraine, with a commercial status as a patented product. Key safety considerations include potential effects on heart rate and blood pressure. Reyvow works by binding to the 5-HT1F receptor, which is involved in the transmission of pain signals. It is not a triptan, but rather a distinct class of medication.

At a glance

Generic nameLASMIDITAN
SponsorEli Lilly
Target5-hydroxytryptamine receptor 1F
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved
First approval2019

Mechanism of action

Lasmiditan binds with high affinity to the 5-HT1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT1F receptor; however, the precise mechanism is unknown.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: